ZEROKEY
1.6.2022 20:08:12 CEST | Business Wire | Press release
ZeroKey today unveiled their second-generation technology, Quantum RTLS™, the world’s most accurate large-scale 3D real-time location system (RTLS). The technology enables unprecedented operational visibility of manufacturing , supply chain, logistics , and human-centric workflows to drive real-time optimization and integration of processes across entire organizations. Quantum RTLS ™ provides hyper-accurate digitization of the location of assets for closed-loop control of highly dynamic workflows, real-time monitoring of human-centric processes, process analytics, and high-fidelity digital twinning.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220601005976/en/
To perform data-driven decision-making, businesses must be able to derive actionable information from the data they are collecting, and that is where ZeroKey’s technology excels. The true value of a connected asset is unlocked through Quantum RTLS™ location technology, enabling an organization to make better-informed and more timely decisions. Through the digitization of both time and location, ZeroKey provides the highest level of accuracy and actionable analytics through its Spatial Intelligence Platform , giving customers 4D operational intelligence that truly delivers on the promise of Industry 4.0.
“The hyper accuracy of Quantum RTLS empowers companies to solve problems that have never been solved before in industrial environments,” says Matthew Lowe, CEO & Co-founder at ZeroKey. “Production efficiency and operational visibility are exponentially increased when operations are digitized in 4D with millimeter accuracy. Our technology enables unprecedented process optimization and quality control, allowing businesses to maximize their output while reducing costly errors.”
Features and benefits of Quantum RTLS™ include:
- Millimeter-level accuracy
- Real-time 3D tracking
- Operational visibility from a globally accessible platform
- Unprecedented analytics and digitization of physical processes
- Wide-area multi-floor/multi-room/multi-building scalability
- Rapid deployments with patented self-calibration technology
- Easy integration of third-party platforms through open API
Quantum RTLS™ will be available on June 30, 2022. For more information, visit https://www.zerokey.com/products/quantum-rtls .
About ZeroKey: ZeroKey’s patented technology, Quantum RTLS™, is the world’s only wide-area, 3D, millimeter-level RTLS technology that closes the IIoT utility gap in factories, warehouses, and industrial environments worldwide, including with six of the largest ten major automotive OEMs. Powered by ultrasonics, Quantum RTLS™ delivers high performance and reliability at any scale with unparalleled simplicity and flexibility. With a range of trackable tags suitable for diverse applications, ZeroKey technology tracks the assets, processes, goods, and personnel critical to modern business with unprecedented resolution. For more information, visit www.zerokey.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005976/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom